Why the study?
Meta-analytic evidence for adjunctive pharmacotherapies to reduce AF recurrence after catheter ablation had never been formally graded, and no cross-class framework existed.
Does adjunctive pharmacotherapy reduce atrial fibrillation recurrence in patients after catheter ablation or cardioversion?
Comparison
Pharmacological agents across eight drug classes
Design
Umbrella review of meta-analyses
Key result
SGLT2 inhibitors provided highly suggestive evidence for reducing atrial fibrillation recurrence after catheter ablation (RR 0.61; 95% CI 0.52-0.71; p=8.0x10^-11).
Authors
Loading...
SGLT2 inhibitors may reduce AF recurrence after ablation; hypothesis-generating and should not yet change practice pending dedicated RCTs.
Systematic Review
Does adjunctive pharmacotherapy reduce atrial fibrillation recurrence in patients after catheter ablation or cardioversion?
Relative Risk: 0.61 (95% CI 0.52–0.71)
p-value: p=8.0x10^-11
SGLT2 inhibitors show highly suggestive evidence for reducing atrial fibrillation recurrence after catheter ablation, highlighting the need for dedicated multicenter trials to establish convincing evidence.
Abdo et al. (2026) conducted a systematic review in Atrial fibrillation recurrence after catheter ablation or cardioversion. Pharmacological agents (including SGLT2 inhibitors) was evaluated on Atrial fibrillation recurrence (RR 0.61, 95% CI 0.52-0.71, p=8.0x10^-11). SGLT2 inhibitors provided highly suggestive evidence for reducing atrial fibrillation recurrence after catheter ablation (RR 0.61; 95% CI 0.52-0.71; p=8.0x10^-11).